SCHEMBL30595268

SCHEMBL30595268

O=C(c1cccnc1-c1ccncn1)N1CCC(F)(Cc2ccc(F)cc2)CC1

nearest known ligand 0.68

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ CYP46A1 Q9Y6A2 11/20 0.68
▸ CYP3A4 P08684 1/20 0.51
▸ CYP2C8 P10632 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ KDM4E B2RXH2 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ VNN1 O95497 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ HTR2A P28223 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24484750 1.00 CYP46A1 (0.68) CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19
SCHEMBL24484253 0.91 CYP46A1 (0.65) CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19
SCHEMBL24484290 0.91 CYP46A1 (0.67) CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19
SCHEMBL14840094 0.90 CYP46A1 (0.84) CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19
SCHEMBL24484722 0.90 CYP46A1 (0.65) CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19
SCHEMBL24484710 0.89 CYP46A1 (0.64) CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19
SCHEMBL24484616 0.88 CYP46A1 (0.62) CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19
SCHEMBL24484707 0.88 CYP46A1 (0.60) CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19
SCHEMBL24484291 0.88 CYP46A1 (0.62) CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19
SCHEMBL24484681 0.87 CYP46A1 (0.61) CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4251618-A1 4-FLUORO-(4-(4-BENZYL)PIPERIDIN-1-YL)(2-(PYRIMIDIN-4-YL)PYRIDIN-3-YL)METHANONE DERIVATIVES AND SIMILAR COMPOUNDS AS CYP46A1 INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Sage Therapeutics, Inc. (US) 2023-10-04 — — EP disclosed
Send feedback